5 Key Takeaways

• 1

  Biologics demand is shifting toward smaller volumes: 47% of commercial products require less than 100 kg annually, and the median marketed antibody requires about 48 kg.

• 2

  Patent expirations from 2026 to 2029 put about $236 billion in global sales at risk, while biosimilar competition can drive down prices and divide markets among manufacturers.

• 3

  Process intensification and single-use systems can support smaller-scale, flexible production; Sartorius estimates they can reduce cleanroom footprint by about 70%.

• 4

  Some companies are building continuous or digitally enabled facilities, but major investments in large stainless-steel plants and 20,000-L bioreactors continue.

• 5

  The article argues that future biologics facilities should prioritize adaptability through modular single-use infrastructure, intensification, automation, process analytics, and AI-enabled decisions.